In these uncertain economic times, UK-focused FTSE 250 stocks are shining like a beacon of stability. With the threat of US tariffs and geopolitical tensions rocking the boat for exporters, domestic-oriented businesses are looking increasingly attractive.
The FTSE 250: A Hidden Gem for Growth-Seeking Investors
While the FTSE 100 often grabs the headlines, the FTSE 250 offers a treasure trove of opportunities for those willing to look beyond the blue-chip giants. And today, we're diving into two stocks that analysts predict could skyrocket by over 100% in the coming year.
But are these forecasts too good to be true? Let's find out.
Future: The Media Giant with a Growth Story
Future, a media powerhouse behind titles like PC Gamer and Cycling Weekly, has had its fair share of challenges in recent years, particularly with the rise of AI impacting e-commerce. However, this has led to an attractive low valuation, and analysts are bullish, with eight out of nine giving it a 'Buy' rating. The average price target? A whopping 1,148p, which translates to a potential gain of 118.7%.
The recent acquisition of SheerLuxe adds a luxurious twist to Future's portfolio, targeting the UK's affluent audiences. With revenue largely derived from domestic sources, Future is well-insulated from foreign market fluctuations. Earnings per share are forecast to reach £1.33 in 2026, a nice bump from the previous year's £1.23.
But the real draw here is the dividend story. With a 3.2% yield that's well-covered by cash earnings, Future offers a rare blend of growth and income potential.
However, the AI threat looms large. Despite Future's efforts to implement cost-saving measures and buyback initiatives, AI remains a persistent risk to its ad-driven revenue stream.
Syncona: Betting Big on Biotech
Syncona is an investor in early-to-mid-stage biotech, with a portfolio valued at over £1 billion, including gene therapies and oncology platforms. Despite a net loss of £25.4 million in the first half of 2025, analysts remain optimistic. The average 12-month price target suggests a 104% increase, driven by asset growth, successful clinical trials, and lucrative partnerships.
Syncona's balance sheet looks robust, with minimal debt and £30 million in free cash flow to fund late-stage investments as the biotech sector recovers. However, this is a speculative and evolving industry, and there's a significant risk of losses if things don't go according to plan.
The upcoming venture capital landscape is notoriously volatile, so investors should approach with caution.
On the positive side, Syncona's UK focus shields it from tariff threats and positions it well to ride the waves of global M&A activity. While currently unprofitable, sales of assets like Freeline could unlock significant value, potentially in the billions.
The Reality Check
Analysts regularly update their targets, so no forecast is set in stone. Future's 118.7% target seems achievable if digital subscriptions rebound, but with the cyclical nature of ads, a more conservative 70-80% gain might be a safer bet.
Syncona's growth is contingent on several biotech catalysts aligning, but the volatile nature of venture capital investments could lead to significant volatility. Achieving a 100%+ gain would require flawless execution in an already turbulent market.
For investors seeking a balance of income and growth, Future seems like a reasonable choice, albeit in a small allocation. Syncona, on the other hand, is a high-risk, high-reward play and should only be considered by those with a robust risk appetite.
As always, diversification is key to weathering economic storms, so a well-rounded portfolio with a mix of stocks is essential.
So, what do you think? Are these stocks worth the risk? Share your thoughts in the comments below!
